Neoadjuvant cisplatin-based chemotherapy followed by selective bladder preservation chemoradiotherapy in muscle-invasive urothelial carcinoma of the bladder: Post hoc analysis of two prospective studies.

person Min Jung Kim Soonchunhyang University Bucheon Hospital, Soonchunhyang University Bucheon Hospital, South Korea info_outline Min Jung Kim, Sung Wook Cho, Sung Hee Lim, Se Hoon Park

Authors person Min Jung Kim Soonchunhyang University Bucheon Hospital, Soonchunhyang University Bucheon Hospital, South Korea info_outline Min Jung Kim, Sung Wook Cho, Sung Hee Lim, Se Hoon Park Organizations Soonchunhyang University Bucheon Hospital, Soonchunhyang University Bucheon Hospital, South Korea, Dankook University Hospital, Cheonan, South Korea, Samsung Medical Center, Seoul, South Korea Abstract Disclosures Research Funding No funding sources reported Background: Bladder preservation chemoradiotherapy (CRT) in patients with a clinical complete response (cCR) following cisplatin-based neoadjuvant chemotherapy (NAC) is a promising treatment strategy for muscle-invasive bladder urothelial carcinoma (MIBC). A combined analysis of raw data from two prospective phase II studies (Sung HH, Investig Clin Urol 2022; Kim H, Cancer Res Treat 2023) was performed to better evaluate the feasibility of selective bladder preservation CRT. Methods: The analysis was based on primary efficacy data from two independent studies, including 76 MIBC patients receiving NAC followed by bladder preservation CRT. The efficacy data included metastasis-free survival (MFS) and disease-free survival (DFS). For the present analysis, starting point of survival was defined as the date of commencing CRT. Results: Among 76 patients, 66 had a cCR following NAC. Sixty-four patients received gemcitabine/cisplatin (GC) combination chemotherapy in neoadjuvant setting, and 12 received nivolumab plus GC. Bladder preservation CRT following NAC was generally well-tolerated, with low urinary tract symptoms being the most common late complication. With a median follow-up of 64 months, recurrence was recorded in 43 patients (57%): intravesical only (n = 20), metastatic only (n = 16), and both (n = 7). In 27 patients with intravesical recurrence, transurethral resection and BCG treatment was given to 17 patients. Salvage cystectomy was performed in 10 patients. Median DFS was 46.3 (95% CI, 25.1-67.5) months, and the median MFS was not reached. Neither DFS nor MFS appeared to be affected by any of the baseline characteristics. However, DFS was significantly longer in patients with a cCR than in those without (HR, 0.465; 95% CI, 0.222-0.976). Conclusions: The strategy of NAC followed by selective bladder preservation CRT based on the cCR is feasible in the treatment of MIBC. A standardized definition of cCR is needed to better assess disease status post-NAC.